This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Oct;9(10):551.

doi: 10.1038/nrclinonc.2012.145. Epub 2012 Aug 14.

Haematological cancer: Better survival, toxicity no worse

Lisa Hutchinson

PMID: 22889971
DOI: 10.1038/nrclinonc.2012.145

Comment

Haematological cancer: Better survival, toxicity no worse

Lisa Hutchinson. Nat Rev Clin Oncol. 2012 Oct.

. 2012 Oct;9(10):551.

doi: 10.1038/nrclinonc.2012.145. Epub 2012 Aug 14.

Author

Lisa Hutchinson

PMID: 22889971
DOI: 10.1038/nrclinonc.2012.145

No abstract available

PubMed Disclaimer

Comment on

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, Hunter AE, Yin J, Craddock CF, Dufva IH, Wheatley K, Milligan D. Burnett AK, et al. J Clin Oncol. 2012 Nov 10;30(32):3924-31. doi: 10.1200/JCO.2012.42.2964. Epub 2012 Jul 30. J Clin Oncol. 2012. PMID: 22851554 Clinical Trial.

References

1. J Clin Oncol. 2012 Nov 10;30(32):3924-31 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.